Company: INSP
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001609550-25-000053
Chunk: 117

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 117
---
 4.    Mine Safety Disclosures.

Not applicable.

Item 5.    Other Information.

(a)  None.

(b)  None.

43

(c)  Adoption or Termination of Trading Arrangements by Directors and Executive Officers

NameTitleActionRule 10b5-1Adoption/ Termination DateAggregate Number of Shares of Common Stock to be SoldExpiration DateShawn T McCormickDirectorAdoptAugust 29, 20256,200(1)August 17, 2026(1) This number includes shares of our common stock issuable pursuant to unvested restricted stock units (“RSU”) that are scheduled to vest during the term of the 10b5-1 plan, subject to time-based vesting conditions set forth in the applicable RSU award agreement.

There were no other "Rule 10b5-1 trading arrangements" or "non-Rule 10b5-1 trading arrangements," as each term is defined in Item 408(a) of Regulation S-K, adopted, modified or terminated by the Company’s directors or "officers" (as defined in Rule 16a-1(f) of the Exchange Act) during the three months ended September 30, 2025.

44

Item 6.    Exhibits. 

ExhibitNumberDescriptionFormFile No.ExhibitFilingDateFiled/FurnishedHerewith3.1 Seventh Amended and Restated Certificate of Incorporation of Inspire Medical Systems, Inc.8-K001-384683.15/7/20183.2 Amended and Restated Bylaws of Inspire Medical Systems, Inc.8-K001-384683.25/7/201810.1 Transition and Separation Agreement by and between Inspire Medical Systems, Inc. and Richard J. Buchholz, dated August 26, 2025.8-K001-3846810.18/26/202531.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section